{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzowg1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzowg1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/24\\\/38\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/24\\\/38\u0022}],\u0022ac\u0022:{\u0022spmdc;14\\\/24\\\/38\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;14\\\/24\\\/38\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/cdn\/css\/http\/css_Xg7z6oCTVgud_Q0huYz9x9iiD5H_2YPSJ5z2ZViSWdY.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EIt is estimated that about two-thirds of patients with hypertension (HTN) are located in the developing world, such as the Caribbean. Despite effective medications and other tools for the management of HTN, the prevalence of poorly controlled HTN remains high. Thus, additional measures are needed to improve the control of HTN, particularly in the developing world. This article discusses the standardization of the Global Standardized Hypertension Treatment Project and the Caribbean Public Health Agency.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EHypertensive Disease\u003C\/li\u003E\u003C\/ul\u003E\u003Cul class=\u0022kwd-group clinical-trial\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003ECardiology \u0026amp; Cardiovascular Medicine\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EHypertensive Disease\u003C\/li\u003E\u003C\/ul\u003E\u003Cp id=\u0022p-2\u0022\u003EIt is estimated that about two-thirds of patients with hypertension (HTN) are located in the developing world, such as the Caribbean. Despite effective medications and other tools for the management of HTN, the prevalence of poorly controlled HTN remains high. Thus, additional measures are needed to improve the control of HTN, particularly in the developing world. Kenneth Connell, MBBS, DM, PhD, Queen Elizabeth Hospital Barbados, Bridgetown, Barbados, discussed the standardization of the Global Standardized Hypertension Treatment Project (GSHTP) and the Caribbean Public Health Agency (CARPHA).\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EIt is estimated that in 2020, 80% of HTN deaths will be in low- to middle-income countries. In addition, there is substantial economic burden that is linked to HTN. In Barbados, 60% of the budget for drugs is applied to treating HTN; yet, HTN is controlled in \u0026lt; 30% of patients. Recent work to address the problem of HTN has focused on updating the guidelines, increasing the focus on the need for blood pressure control, and increasing government involvement. Despite these efforts, the control of HTN remains inadequate.\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EThe GSHTP began in April 2014 and is focused on making the \u201cprocess\u201d of treating HTN more efficient. It aims to improve the control of HTN by identifying a core set of medications, making those medications widely available, improving the delivery of care, and increasing the use of medications. Data collected from the Winston Scott Polyclinic and the Edgar Cochrane Polyclinic, including the direct observation of physician practice, medical records, health care provider questionnaires, and interviews with stakeholders, helped to inform the development of the CARPHA HTN guidelines. It is hoped that these guidelines will encourage providers to use new treatment protocols and create systems to track the use of these protocols. These guidelines are expected to be published in late 2014.\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EAlthough there are multiple guidelines that have been updated recently for the management of HTN, Prof. Connell pointed out that there are differences among these guidelines, and there is a need for a regionally specific guideline informed by regional data.\u003C\/p\u003E\u003Cp id=\u0022p-6\u0022\u003EPragna Patel, MD, MPH, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA, further discussed the goals of the GSHTP. The GSHTP was conceived following a World Health Organization assembly focused on noncommunicable diseases and was formed with a goal of reducing HTN by 25% by the year 2025.\u003C\/p\u003E\u003Cp id=\u0022p-7\u0022\u003EMultiple patient-, provider- and systems-based barriers to blood pressure control have been identified. For example, patients may have limited access to care or have poor adherence to treatment. Health care providers may be reluctant to treat an asymptomatic condition, have insufficient time with individual patients, or fail to follow guidelines. In addition, patients often have poor follow-up and difficulty obtaining medications. Health systems fail to use nurses and other providers who can assist in the management of hypertension.\u003C\/p\u003E\u003Cp id=\u0022p-8\u0022\u003EIn response to these barriers, the GSHTP has developed a framework based on prior experience with tuberculosis that includes a structured approach to deliver high-quality and standardized health care with sufficient support systems [Seita A, Harries AD. \u003Cem\u003EInt J Tuberc Lung Dis\u003C\/em\u003E 2013]. In addition, the GSHTP has created treatment targets and indicators to expand services and reduce the overall burden of disease.\u003C\/p\u003E\u003Cp id=\u0022p-9\u0022\u003EA similar framework was applied by the Kaiser Permanente Northern California HTN organization that resulted in an increase of HTN control from 44% to 80% [Jaffe MG et al. \u003Cem\u003EJAMA\u003C\/em\u003E 2013]. The 6 care processes that were implemented to achieve this substantial improvement were the development of an evidence-based treatment guideline, initiation of an HTN registry, development of a performance measure, dissemination of these quality improvement initiatives, promotion of a single-pill combination therapy to improve adherence, and development of blood pressure checks by nonphysicians.\u003C\/p\u003E\u003Cp id=\u0022p-10\u0022\u003EThe goal of the framework of the GSHTP is to standardize the pharmacologic treatment of HTN and to encourage the use of evidence-based guidelines. The core medications were categorized based on whether therapies were considered first line or backup. These medications were then further classified based on class and whether fixed combinations were available as a single pill.\u003C\/p\u003E\u003Cp id=\u0022p-11\u0022\u003ETo facilitate the availability of medications, the Pan American Health Organization (PAHO) Strategic Fund was created to procure the medications at a low cost for Latin America. Countries within this region can choose to purchase HTN medications through the fund. Following a workshop with GSHTP, the PAHO Strategic Fund added 4 of the primary medications and 3 of the backup medications on the core medication list to the fund\u0027s procurement.\u003C\/p\u003E\u003Cp id=\u0022p-12\u0022\u003ETo improve the treatment of HTN, GSHTP held a workshop to assess several key elements, including standard treatment guidelines, creating registries and information systems, standardizing medications and making them available, encouraging patient-centeredness to improve self-management interventions, improving the organizational management of care systems, and promoting community involvement. In addition, a clinical toolkit was developed by the GSHTP for health care providers and administrators that included an overview of HTN, webi-nars on using registries and standardized treatment protocols, educational materials for providers and patients, and clinical tools for managing HTN and improving patient adherence to medications. This toolkit will be available on the US Centers for Disease Control and Prevention website.\u003C\/p\u003E\u003Cp id=\u0022p-13\u0022\u003EIn conclusion, Dr. Patel highlighted that the goal of the GSHTP is to develop a framework for managing HTN that is feasible and able to be used throughout the developing world. In addition, she stressed that the GSHTP is not meant to replace any current HTN guidelines but is to facilitate the control of HTN.\u003C\/p\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2014 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/14\/24\/38.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzowg1\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}